Skip to main content
BIXT logo

BIXT · Bioxytran, Inc

Track BIXT — free
$0.02 +0.00 (+0.96%) At close · Sep 2
Market Cap
$2.39M
Shares
114.70M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.02 Open$0.02 Day$0.02–0.02 52W close$0.02–0.09 Avg vol 30d127K Short int130 · 0.0% float · 1.0d Short vol0% DataJan 2020–Sep 2026 Filing10-Q · Aug 14

Up next

filed Aug 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$177,794
Trailing 12 months
Net income (TTM)
−$3.49M
Trailing 12 months
Revenue growth YoY
-48.5%
Year over year
Operating margin
-162.5%
Trailing 12 months
P / E (TTM)
Trailing earnings
FCF yield
TTM · current market cap
Return on invested capital
Trailing 12 months
Net cash
Latest balance sheet
Dividend yield
Trailing 12 months
Shares change YoY
+28.7%
Year over year · more shares
Price change (1Y)
-71.8%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.2 · calm Equity put/call 0.56
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −52%
below
Price vs 50-day avg −14%
below
RSI (14) 44
neutral
MACD trend Negative
52-week position 0%
near low
Momentum
relative strength
Very Weak
1-month return −4%
trailing
6-month return −48%
trailing
YTD return −72%
this year
Relative strength −62%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.00% of float · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Squeeze score 8
low risk · 0–100
Fundamentals
Fair
Revenue growth −22%
Y/Y
Gross margin 46%
contracting
EPS growth 0%
Y/Y
Quant / Vol
risk profile
Very High
Volatility 118%
annualized · 1-yr
Max drawdown −77%
past year
ATR 10.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−52% Bearish
Price vs 50-day avg
−14% Bearish
RSI (14)
44 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.00% of float · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $0
vs 200-day avg -52% vs 50-day avg -14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BIXT
Bioxytran, Inc
this stock
$2.39M -72.2% -22.5% 0.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
$140.51B +22.8% +46.2% 32.3 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
$84.82B +10.4% +20.8% 20.4 2.3%
ARGX
Argenx SE
$65.63B +25.5% 1.9%
CSLLY
Csl Ltd
$59.96B 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest Rising
Shares short
130
Days to cover
1.0d
Change
+130 sh
View
Short Volume
Short vol %
0%
As of
Sep 2, 2026
Short Total
View
Fails to Deliver
FTD shares
60.0K
Value
$2.4K
As of
Mar 19, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$191.1K
Net income (FY)
$-2.1M
EPS diluted
$-0.02
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 14, 2026
This year
10
View
Exempt Offerings
Offering
$6.0M
Filed
Mar 13, 2023
View

Performance

5D 20D 120D MTD YTD
BIXT -7.5% -4.1% -47.5% +1.4% -72.2%
SPY -0.1% -0.6% +14.9% -0.3% +12.2%
vs SPY -7.3% -3.5% -62.4% +1.7% -84.4%
Key facts CIK 1445815 CUSIP 09075D102 Visit website Investor relations